142 related articles for article (PubMed ID: 31588102)
1. [A Pulmonary Mucoepidermoid Carcinoma with Anaplastic Lymphoma Kinase Fusion Responding to Alectinib Hydrochloride].
Onodera K; Sato N; Kobayashi K; Kurotaki H
Kyobu Geka; 2019 Oct; 72(11):889-892. PubMed ID: 31588102
[TBL] [Abstract][Full Text] [Related]
2. Large Cell Neuroendocrine Carcinoma Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement with Response to Alectinib.
Hayashi N; Fujita A; Saikai T; Takabatake H; Sotoshiro M; Sekine K; Kawana A
Intern Med; 2018 Mar; 57(5):713-716. PubMed ID: 29151522
[TBL] [Abstract][Full Text] [Related]
3. ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature.
Mamesaya N; Nakashima K; Naito T; Nakajima T; Endo M; Takahashi T
BMC Cancer; 2017 Jul; 17(1):471. PubMed ID: 28683775
[TBL] [Abstract][Full Text] [Related]
4. Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase rearrangement-positive non-small cell lung cancer treated with alectinib.
Yamamoto Y; Okamoto I; Otsubo K; Iwama E; Hamada N; Harada T; Takayama K; Nakanishi Y
Invest New Drugs; 2015 Oct; 33(5):1148-50. PubMed ID: 26334220
[TBL] [Abstract][Full Text] [Related]
5. Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report.
Honda K; Kadowaki S; Kato K; Hanai N; Hasegawa Y; Yatabe Y; Muro K
Invest New Drugs; 2019 Aug; 37(4):791-795. PubMed ID: 30790150
[TBL] [Abstract][Full Text] [Related]
6. Successful Alectinib Treatment for Carcinoma of Unknown Primary with
Sugiyama K; Izumika A; Iwakoshi A; Nishibori R; Sato M; Shiraishi K; Hattori H; Nishimura R; Kitagawa C
Curr Oncol; 2021 May; 28(3):1938-1945. PubMed ID: 34064158
[TBL] [Abstract][Full Text] [Related]
7. Interstitial lung disease induced by alectinib (CH5424802/RO5424802).
Ikeda S; Yoshioka H; Arita M; Sakai T; Sone N; Nishiyama A; Niwa T; Hotta M; Tanaka T; Ishida T
Jpn J Clin Oncol; 2015 Feb; 45(2):221-4. PubMed ID: 25398579
[TBL] [Abstract][Full Text] [Related]
8. Transformation to small-cell lung cancer as a mechanism of acquired resistance to crizotinib and alectinib.
Miyamoto S; Ikushima S; Ono R; Awano N; Kondo K; Furuhata Y; Fukumoto K; Kumasaka T
Jpn J Clin Oncol; 2016 Feb; 46(2):170-3. PubMed ID: 26613679
[TBL] [Abstract][Full Text] [Related]
9. [Three cases of pulmonary mucoepidermoid carcinoma].
Nagahiro I; Ando A; Ichiba S; Aoe M; Date H; Shimizu N
Kyobu Geka; 2000 Jul; 53(8 Suppl):702-5. PubMed ID: 10935391
[TBL] [Abstract][Full Text] [Related]
10. [Mucoepidermoid carcinoma with high level of serous carcinoembryonic antigen; report of a case].
Noriyuki T; Okumichi T; Kimura A; Koga R; Takeshima Y
Kyobu Geka; 2005 Jul; 58(7):592-5. PubMed ID: 16004345
[TBL] [Abstract][Full Text] [Related]
11. The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.
Gadgeel SM
Future Oncol; 2018 Aug; 14(18):1875-1882. PubMed ID: 29536761
[TBL] [Abstract][Full Text] [Related]
12. Successful oral desensitization against skin rash induced by alectinib in a patient with anaplastic lymphoma kinase-positive lung adenocarcinoma: A case report.
Shirasawa M; Kubotaa M; Harada S; Niwa H; Kusuhara S; Kasajima M; Hiyoshi Y; Ishihara M; Igawa S; Masuda N
Lung Cancer; 2016 Sep; 99():66-8. PubMed ID: 27565916
[TBL] [Abstract][Full Text] [Related]
13. [Successful treatment of bronchial mucoepidermoid carcinoma by bronchoplasty].
Yamada T; Chiba W; Yasuba H; Shimada T; Kudo M; Hamada K; Yamashita K; Kita H; Hitomi S
Kyobu Geka; 2005 Jul; 58(7):531-6. PubMed ID: 16004333
[TBL] [Abstract][Full Text] [Related]
14. Dramatic response to alectinib in a patient of ALK-rearranged lung cancer with poor performance status.
Tanaka H; Taima K; Morimoto T; Nakamura K; Tanaka Y; Itoga M; Takanashi S; Okumura K
BMC Res Notes; 2016 Mar; 9():173. PubMed ID: 26987388
[TBL] [Abstract][Full Text] [Related]
15. Alectinib is effective, safe and tolerable in an adolescent with stage IVB ALK-rearranged adenocarcinoma of the lung.
Balzer BWR; Loo C; Wegner EA; Nath CE; Lee S; Smith C; Lewis CR; Trahair TN; Anazodo AC
Pediatr Hematol Oncol; 2018; 35(7-8):415-421. PubMed ID: 30526220
[TBL] [Abstract][Full Text] [Related]
16. Apatinib reverses alectinib resistance by targeting vascular endothelial growth factor receptor 2 and attenuating the oncogenic signaling pathway in echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene-positive lung cancer cell lines.
Chen Y; Ma G; Su C; Wu P; Wang H; Song X; Yu Q; Zeng A; Zhou S
Anticancer Drugs; 2018 Nov; 29(10):935-943. PubMed ID: 30074936
[TBL] [Abstract][Full Text] [Related]
17. [Alectinib for an Octogenarian Patient with Poor Performance Status and ALK Fusion Gene-Positive Lung Cancer-A Case Report].
Kamiyoshihara M; Igai H; Matsuura N; Yazawa T; Ohsawa F
Gan To Kagaku Ryoho; 2021 Aug; 48(8):1053-1055. PubMed ID: 34404075
[TBL] [Abstract][Full Text] [Related]
18. Anaplastic Lymphoma Kinase-Positive Lung Cancer with Mucoepidermoid Carcinoma Differentiation: A Case Report.
Sakatani T; Masuda Y; Morikawa T; Usui K
Case Rep Oncol; 2020; 13(2):1037-1041. PubMed ID: 33082745
[TBL] [Abstract][Full Text] [Related]
19. [Successful alectinib monotherapy for residual disease after brentuximab vedotin combined chemotherapy in ALK-positive anaplastic large cell lymphoma].
Sakata M; Saburi M; Kawano K; Takata H; Miyazaki Y; Nagamatsu K; Gamachi A; Ohtsuka E
Rinsho Ketsueki; 2022; 63(8):855-859. PubMed ID: 36058854
[TBL] [Abstract][Full Text] [Related]
20. Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer.
Nishio M; Nakagawa K; Mitsudomi T; Yamamoto N; Tanaka T; Kuriki H; Zeaiter A; Tamura T
Lung Cancer; 2018 Jul; 121():37-40. PubMed ID: 29858024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
